Multinational clinical trials, including EMBRACE and PARADIGM, are enrolling participants across Europe and the US, supported by regulatory approvals.
3 reports, 1 independent
Updated Aug 14
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Multinational clinical trials, including EMBRACE and PARADIGM, are enrolling participants across Europe and the US, supported by regulatory approvals.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Cybin approaches clinical trials across the United States.Sub-event
EMBRACE and PARADIGM clinical trials are expanding across Europe and the US with regulatory approvals.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- Business WireCybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results Cybin continues to make significant progress on its journey to bring breakthrough therapies to
- Business WireCybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - EMBRACE, the second study within the Phase 3
- Business WireCybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - EMBRACE, the second Phase 3 study with